|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
10
|
|
pubmed:dateCreated |
2000-1-4
|
|
pubmed:abstractText |
To compare vinblastine versus the combination of vinblastine plus estramustine as treatment for patients with hormone-refractory prostate cancer (HRPC).
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Oct
|
|
pubmed:issn |
0732-183X
|
|
pubmed:author |
pubmed-author:AnsariRR,
pubmed-author:BalshamAA,
pubmed-author:DuganWW,
pubmed-author:EinhornLL,
pubmed-author:EntmacherMM,
pubmed-author:HannaMM,
pubmed-author:HudesGG,
pubmed-author:LoehrerPP,
pubmed-author:MonacoFF,
pubmed-author:RamseyHH,
pubmed-author:RoseWW,
pubmed-author:RothBB,
pubmed-author:SprandioJJ
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
17
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
3160-6
|
|
pubmed:dateRevised |
2006-4-24
|
|
pubmed:meshHeading |
pubmed-meshheading:10506613-Administration, Oral,
pubmed-meshheading:10506613-Adult,
pubmed-meshheading:10506613-Aged,
pubmed-meshheading:10506613-Aged, 80 and over,
pubmed-meshheading:10506613-Antineoplastic Agents, Phytogenic,
pubmed-meshheading:10506613-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:10506613-Disease Progression,
pubmed-meshheading:10506613-Drug Administration Schedule,
pubmed-meshheading:10506613-Estramustine,
pubmed-meshheading:10506613-Humans,
pubmed-meshheading:10506613-Injections, Intravenous,
pubmed-meshheading:10506613-Male,
pubmed-meshheading:10506613-Middle Aged,
pubmed-meshheading:10506613-Neoplasm Recurrence, Local,
pubmed-meshheading:10506613-Prostate-Specific Antigen,
pubmed-meshheading:10506613-Prostatic Neoplasms,
pubmed-meshheading:10506613-Survival Analysis,
pubmed-meshheading:10506613-Treatment Outcome,
pubmed-meshheading:10506613-Vinblastine
|
|
pubmed:year |
1999
|
|
pubmed:articleTitle |
Vinblastine versus vinblastine plus oral estramustine phosphate for patients with hormone-refractory prostate cancer: A Hoosier Oncology Group and Fox Chase Network phase III trial.
|
|
pubmed:affiliation |
The Fox Chase Network and Division of Biostatistics, Fox Chase Cancer Center, Philadelphia, PA 19111, USA.
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Randomized Controlled Trial,
Multicenter Study,
Clinical Trial, Phase III
|
